A double-blind cross-over trial of Prenazone (DA 2370) and phenylbutazone in rheumatoid arthritis

Abstract

A short-term double-bind cross-over trial of prenazone 600 mg daily and phenylbutazone 300 mg daily was carried out in twenty out-patients with rheumatoid arthritis. Ten patients preferred prenazone, and eight preferred phenylbutazone. No significant difference in analgesic and antiinflammatory potency was demonstrated under the conditions of the trial, and no serious adverse effects, either clinical or laboratory, were encountered. These findings support other claims that prenazone may be a useful alternative in the treatment of rheumatoid arthritis.